Results 91 to 100 of about 2,007,940 (182)

Dapivirine Levonorgestrel Vaginal Ring: A multipurpose prevention ring for HIV and contraceptive protection [PDF]

Leveraging our experience developing the monthly dapivirine vaginal ring (DVR or “PrEP ring”), which received a positive opinion from the European Medicines Agency in 2020 for women’s HIV risk reduction, the Population Council is developing a 3-month ...
IPM South Africa
core   +1 more source

Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
Variable adherence limits effectiveness of daily oral and intravaginal tenofovir-containing pre-exposure prophylaxis. Monthly vaginal antiretroviral rings are one approach to improve adherence and drug delivery.MTN-013/IPM 026, a multisite, double-blind, randomized, placebo-controlled trial in 48 HIV-negative US women, evaluated vaginal rings ...
Beatrice A, Chen, Lori, Panther, Mark A, Marzinke, Craig W, Hendrix, Craig J, Hoesley, Ariane, van der Straten, Marla J, Husnik, Lydia, Soto-Torres, Annalene, Nel, Sherri, Johnson, Nicola, Richardson-Harman, Lorna K, Rabe, Charlene S, Dezzutti   +12 more
openaire   +2 more sources

Men’s Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe

AIDS and Behavior, 2021
The dapivirine vaginal ring has been well-tolerated and shown to prevent HIV in clinical trials. The ring is female initiated, yet endorsement for use is sought from male partners in many relationships. In clinical studies, participants have expressed worries about men detecting rings during vaginal sex, which introduces concerns about product use ...
Elizabeth T. Montgomery, Ariana W. K. Katz, Zoe Duby, Leila E. Mansoor, Neetha S. Morar, Kalendri Naidoo, Mercy Tsidya, Miria Chitukuta, Victor Guma, Siyanda Tenza, Jonah Leslie, Morgan Garcia, Sarita Naidoo   +12 more
openaire   +3 more sources

Drug stability and product performance characteristics of a dapivirine-releasing vaginal ring under simulated real-world conditions

, 2019
In two recent Phase III clinical trials, use of a 25 mg dapivirine vaginal ring significantly reduced HIV acquisition rates. Post hoc analysis from one of the trials indicated higher rates of protection among women over the age of 21 years when compared ...
Boyd, Peter, Spence, Patrick, McCoy, Clare F.; id_orcid, Derrick, Tiffany, Murphy, Diarmaid J., Devlin, Brid, Malcolm, R. Karl; id_orcid   +6 more
core   +1 more source

3-Month Dapivirine Vaginal Ring: A longer-acting dapivirine vaginal ring for HIV protection [PDF]

Leveraging our experience developing the monthly dapivirine vaginal ring (DVR or PrEP ring ), which received a positive opinion from the European Medicines Agency (EMA) in 2020 for women’s HIV risk reduction, the Population Council has developed a 3 ...
IPM South Africa
core   +1 more source

Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis

Journal of the International AIDS Society, Volume 28, Issue S2, July 2025.
Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) in two clinical trials. This analysis projects the impact of expanding PrEP coverage with CAB‐LA in South Africa between 2022 ...
Sarah E. Stansfield, Mia Moore, Lise Jamieson, Gesine Meyer‐Rath, Leigh F. Johnson, David Kaftan, Anna Bershteyn, Jennifer Smith, Valentina Cambiano, Loveleen Bansi‐Matharu, Andrew Phillips, Jesse Heitner, Ruanne V. Barnabas, Brett Hanscom, Deborah J. Donnell, Marie‐Claude Boily, Dobromir Dimitrov   +16 more
wiley   +1 more source

Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
Objective: To evaluate the potential for a clinically relevant drug–drug interaction with concomitant use of a dapivirine vaginal ring, a novel antiretroviral-based HIV-1 prevention strategy, and hormonal contraception by examining contraceptive efficacies with and without dapivirine ring use ...
Jennifer E, Balkus, Thesla, Palanee-Phillips, Krishnaveni, Reddy, Samantha, Siva, Ishana, Harkoo, Clemensia, Nakabiito, Kenneth, Kintu, Gonasangrie, Nair, Catherine, Chappell, Flavia Matovu, Kiweewa, Samuel, Kabwigu, Logashvari, Naidoo, Nitesha, Jeenarain, Mark, Marzinke, Lydia, Soto-Torres, Elizabeth R, Brown, Jared M, Baeten   +16 more
openaire   +2 more sources

Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES

, 2019
The past fifteen years have witnessed a resurgence of interest in vaginal ring technologies for drug delivery applications, mostly driven by the impetus for development of vaginally-administered antiretroviral microbicides to help reduce the high ...
Offord, Robin E., Boyd, Peter, Hartley, Oliver, Kett, Vicky L, McBride, John W, McBride, John W., Malcolm, R Karl, Cameron, David, Offord, Robin Ewart, Kett, Victoria L.; id_orcid, Dias, Nicola, Malcolm, R. Karl; id_orcid, Devlin, Brid   +12 more
core   +1 more source

Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe

Aids and Behavior
Pregnant and lactating persons in sub-Saharan Africa face a heightened risk of HIV acquisition, due to biological and behavioral factors, combined with limited access to prevention and treatment services.
Alinda M. Young, Marie C. D. Stoner, Florence Mathebula, Rebone Mohuba, Alejandro Baez, L. Seyama, Prisca Mutero, J. Etima, Zayithwa Fabiano, Lee Fairlie, Ashley J. Mayo, Jennifer E. Balkus, Mei Song, Katie Bunge, Jeanna M. Piper, Iván C. Balán, A. van der Straten, Elizabeth T. Montgomery   +17 more
semanticscholar   +1 more source

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls

AIDS, 2020
Objective: The antiretroviral-based dapivirine vaginal ring reduced HIV risk among women in phase III clinical trials. However, limited data exists on the impact of dapivirine on the vaginal microenvironment in adolescents. Design: A comprehensive metaproteomics approach was used to
Farr Zuend, Christina, Noël-Romas, Laura, Hoger, Sarah, McCorriser, Stuart, Westmacott, Garrett, Marrazzo, Jeanne, Hillier, Sharon L., Dezzutti, Charlene, Squires, Kathleen, Bunge, Katherine E., Burgener, Adam   +10 more
openaire   +3 more sources